Evidence map›Paper›PMID 32316255›Full record

ArticleMolecules (Basel, Switzerland)2020

Combination Therapy of Acarbose and Cyclosporine a Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice.

Hsin-Hua Chen, Chi-Chien Lin, Yu-Tang Tung, Ya-Hsuan Chao, Wen-Ching Huang, Po-Ying Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Ixekizumab May Improve Renal Function in Psoriasis.Healthcare (Basel, Switzerland) · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Hsin-Hua ChenDepartment of Medical Research, Taichung Veterans General Hospital, Taichung 407, Taiwan.ORCID 0000-0002-7304-4587
Chi-Chien LinInstitute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan.ORCID 0000-0002-1464-0231
Yu-Tang TungGraduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0002-4780-6496
Ya-Hsuan ChaoInstitute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan.
Wen-Ching HuangDepartment of Exercise and Health Science, National Taipei University of Nursing and Health Sciences, Taipei 112, Taiwan.
Po-Ying LeeDivision of Plastic Surgery, Department of Surgery, Cathay General Hospital, Taipei 280, Taiwan.
National Chung Hsing University · TWCathay General Hospital · TWNational Taipei University of Nursing and Health Science · TWTaichung Veterans General Hospital · TWTaipei Medical University Hospital · TW

Funding

Ministry of Science and Technology of Taiwan MOST 107-2628-H-038-001-MY3Taipei Medical University 106-6820-001-112
6 · The paper itself

Abstract

Moderate to severe psoriasis, an immune-mediated inflammatory disease, adversely affects patients' lives. Cyclosporin A (CsA), an effective immunomodulator, is used to treat psoriasis. CsA is ineffective at low doses and toxic at high doses. Acarbose (Acar), a common antidiabetic drug with anti-inflammatory and immunomodulatory effects, reduces imiquimod (IMQ)-induced psoriasis severity. Combinations of systemic drugs are generally more efficacious and safer than higher doses of single drugs. We observed that mice treated with a combination of Acar (250 mg/kg) and low-dose CsA (10 or 20 mg/kg) exhibited significantly milder IMQ-induced psoriasis-like dermatitis and smoother back skin than those treated with Acar (250 mg/kg), low-dose CsA (10 or 20 mg/kg), or IMQ alone. The combination therapy significantly reduced serum and skin levels of Th17-related cytokines (interleukin (IL)-17A, IL-22, and IL-23) and the Th1-related cytokine tumor necrosis factor-α (TNF-α) compared with Acar, low-dose CsA, and IMQ alone. Additionally, the combination therapy significantly reduced the percentages of IL-17- and IL-22-producing CD4

Indexed as

AcarboseAnimalsAnti-Inflammatory AgentsCyclosporineCytokinesDisease Models, AnimalDrug Therapy, CombinationGene Expression RegulationHumansImiquimodMaleMicePsoriasisT-Lymphocytes, RegulatoryTumor Necrosis Factor-alphaAcarboseAnti-Inflammatory AgentsCyclosporineCytokinesImiquimodTnf protein, mouseTumor Necrosis Factor-alphaacarbosecombination therapycyclosporineimiquimodpsoriasis

Identifiers

PMID32316255
PMCPMC7221909
OpenAlexW3017225939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.